Autor(es): Rasonglès Patrice, Angelini-Tibert Marie France, Simon Philip, Currie Caroline, Isola Herve, Kientz Daniel, Slaedts Marc, Jacquet Michele, Sundin David, Lin Lily, Corash Laurence, Cazenave Jean Pierre

Resumo: During the Chikungunya virus (CHIKV) epidemic on Ile de La Réunion, France, more than 30% of 750,000 inhabitants were infected. Local blood donation was suspended to prevent transfusion-transmitted infection (TT-CHIKV). To sustain the availability of platelet (PLT) components, the Etablissement Français du Sang implemented universal pathogen inactivation (INTERCEPT, Cerus Europe BV) of PLT components (CPAs). The study assessed the safety of PLT components treated with pathogen inactivation transfused in routine clinical practice. This was a retrospective observational study using patient medical records - the AFSSAPS hemovigilance database (eFIT) to identify TT-CHIKV - adverse events (AEs) classified as acute transfusion reactions (ATRs) to PLT components prepared with pathogen inactivation. During 1 year, 1950 INTERCEPT-CPAs were transfused to 335 adult, 51 pediatric, - 41 infant patients. Nineteen AEs were observed in 15 patients - 10 were classified as ATRs. Eight ATRs occurred in 6 pediatric hematology-oncology patients. No ATRs were observed in infants. The most frequently reported signs - symptoms were Grade 1 urticaria, itching, chills, fever, - anxiety. No cases of transfusion-related acute lung injury, TT-sepsis, or TT-CHIKV were detected. INTERCEPT-CPAs were well tolerated in a broad range of patients, including infants. ATR incidence was low - when present ATRs were of mild severity.

Imprenta: Transfusion, v. 49, n. 6, p. 1083-1091, 2009

Identificador do objeto digital: 10.1111/j.1537-2995.2009.02111.x

Descritores: Chikungunya virus - Viral infections ; Chikungunya Virus - Virus ; Chikungunya virus - Chikungunya fever ; Chikungunya virus - Epidemic ; Chikungunya virus - Epidemiology ; Chikungunya virus - Public health

Data de publicação: 2009

INDICADORES

ACESSO